Mode
Text Size
Log in / Sign up
N/A N=60

Evaluation of Cognitive State Using Neurosteer EEG System

Cognitive Decline

Enrolled (actual)
60
Serious AEs
0.0%
Results posted
Mar 2021
Primary outcome: Primary: Correlation Between Cognition Level Changes as Evaluated by Current Clinical Tools (i.e. MMSE) and Brain Activity Features Extracted Using the Neurosteer Technology. — -0.3570; 0.3617 Pearson correlation coefficient

Study Design & Population

Study type
Observational
Phase
N/A
Interventions
Neurosteer Aurora system (Device)
Age
Adult, Older Adult · 45+ yrs
Sex
All
Sponsor
Neurosteer Ltd.
Primary completion
Jul 2020

Outcome Measures

OutcomeResultp-value
PRIMARY
Correlation Between Cognition Level Changes as Evaluated by Current Clinical Tools (i.e. MMSE) and Brain Activity Features Extracted Using the Neurosteer Technology.
-0.3570; 0.3617
SECONDARY
Usability and Tolerability of the Neurosteer System in the Elderly Population
SECONDARY
Overall Brain Activity in Patients
SECONDARY
Overall Response to Auditory Stimulation

Summary

This is an observational study. Patients who fulfill all inclusion criteria and none of the exclusion criteria will be enrolled in the study, be neurologically evaluated and will go through EEG recordings while listening to an auditory cognitive assessment tool and preforming tasks. EEG recordings will be analyzed using proprietary computational analyses.

Eligibility Criteria

Inclusion Criteria

  • Men and women over the age of 45.
  • MMSE score < 30.
  • MMSE score ≥ 10.
  • Patient is able to collaborate.
  • No other cognitive comorbidity.
  • No seizure event.

Exclusion Criteria

  • Advanced stage of cognitive decline (MMSE < 10).
  • Any verbal or non-verbal form of objection from patient or form patient's family member or significant other.
  • Presence of several cognitive comorbidity.
  • Damage to integrity of scalp and/or skull.
  • Skin irritation in the facial and forehead area.
  • Significant hearing impairments.
  • History of drug abuse.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT04386902). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search